~~<i id='61D9D89AE1'><strike id='61D9D89AE1'><tt id='61D9D89AE1'><pre id='61D9D89AE1'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

comprehensive

author：fashion 2025-09-05 07:00:43 - browse：785

Calling Bullshit course University of Washington — Screenshot via callingbullshit.org

Tired of alternative facts, fake news, and breathless hyperbole, two professors at the University of Washington are trying to strike a blow for science.

Their weapon? A new course: “Calling Bullshit In the Age of Big Data.”

The class website and colorful syllabus went online last month and almost instantly went viral.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： The best solution to the drug shortages problem

focus

explore

focus

entertainment

focus

AdobePrivateMedicarejustisn’tthegoldmineitoncewas.Caseinpoint:CanoHealth,acompanyoncevaluedat$4.4bil

WSS

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Readout Newsletter: Amgen, Regeneron, BGI Group and more

The Biogen Aduhelm mess could happen again

Bernie brings in new pharma CEOs to talk drug prices

Police still searching for prisoner who escaped from NYC hospital

Devoted Health’s losses in Medicare Advantage persist

entertainment

comprehensive

focus

Wildfire smoke exposes gaps in outdoor worker protections

Padmanee Sharma of MD Anderson at center of lawsuit over credit

The cancer drug shortage isn’t new — and neither are the solutions

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Moonlake's readout produced a cash windfall. Risks remain

American woman, child freed after being kidnapped in Haiti last month

New air purifier tech could be key to improving indoor air quality

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Naloxone nonprofit donates 200,000 doses after FDA approval

explore

Why Novartis is going to walk from its acquisition of MorphoSys

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Wegovy’s successful heart trial raises vital question about weight loss

Man killed during FBI raid in connection with threats against Biden, other officials

What’s missing from the debate over nursing home staff minimums

explore

focus

entertainment

focus